Your browser is no longer supported. Please, upgrade your browser.
Settings
CRSP CRISPR Therapeutics AG daily Stock Chart
CRSP [NASD]
CRISPR Therapeutics AG
Index- P/E- EPS (ttm)-2.35 Insider Own2.40% Shs Outstand50.93M Perf Week3.72%
Market Cap1.61B Forward P/E- EPS next Y-3.58 Insider Trans-3.33% Shs Float30.52M Perf Month-10.96%
Income-111.00M PEG- EPS next Q-0.78 Inst Own47.40% Short Float16.14% Perf Quarter-13.60%
Sales35.30M P/S45.48 EPS this Y18.10% Inst Trans-0.96% Short Ratio6.14 Perf Half Y-33.02%
Book/sh8.81 P/B3.58 EPS next Y-9.10% ROA-30.90% Target Price57.15 Perf Year-21.61%
Cash/sh9.57 P/C3.29 EPS next 5Y- ROE-40.40% 52W Range22.22 - 73.90 Perf YTD10.33%
Dividend- P/FCF- EPS past 5Y- ROI-32.00% 52W High-57.35% Beta-
Dividend %- Quick Ratio15.40 Sales past 5Y- Gross Margin- 52W Low41.85% ATR1.77
Employees127 Current Ratio15.40 Sales Q/Q-75.00% Oper. Margin- RSI (14)47.99 Volatility3.75% 5.24%
OptionableYes Debt/Eq0.00 EPS Q/Q-73.60% Profit Margin- Rel Volume0.52 Prev Close30.93
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume802.10K Price31.52
Recom2.50 SMA20-2.16% SMA50-1.83% SMA200-30.91% Volume416,499 Change1.91%
Jan-28-19Downgrade Goldman Buy → Neutral
Jan-22-19Downgrade Citigroup Neutral → Sell
Nov-30-18Initiated Needham Buy $62
Oct-10-18Initiated Wells Fargo Outperform $65
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Underperform
May-15-18Reiterated Chardan Capital Markets Buy $25 → $72.50
Apr-06-18Initiated Goldman Buy $86
Mar-08-18Initiated JMP Securities Mkt Outperform $69
Jan-23-18Upgrade SunTrust Hold → Buy
Dec-22-17Initiated Piper Jaffray Overweight
Jul-14-17Initiated SunTrust Hold $16
Mar-28-17Initiated Chardan Capital Markets Buy $23.50
Feb-14-19 12:01PM  Is Moderna a Buy? Motley Fool
Feb-12-19 07:49AM  Jim Cramer Gives His Opinion On Cronos, Etsy And More Benzinga
Feb-11-19 12:36PM  Here's Why CRISPR Therapeutics Rose 13.5% in January Motley Fool
Feb-09-19 10:03AM  Should Sangamo's Failure Make CRISPR Investors Nervous? Motley Fool
Feb-07-19 03:33PM  Vertex Pharmaceuticals: New Drug, Same Great Growth Story Motley Fool -8.73%
Feb-06-19 10:31AM  Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales Zacks
Feb-05-19 06:00AM  Why Even a Pessimistic Analyst Thinks CRISPR Therapeutics Will Jump 20% Motley Fool
Feb-03-19 02:04PM  3 Gene Therapy Stocks With Huge Catalysts in 2019 Motley Fool
Feb-01-19 01:53PM  3 Biotech Stocks That Are Set for a Breakthrough InvestorPlace
Jan-30-19 10:02AM  Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks
Jan-28-19 04:16PM  CRISPR Stocks Flattened After 1 Downgraded Amid Steep Rivalry Investor's Business Daily -6.11%
09:33AM  Goldman Sachs Steps To The Sidelines On Crispr Therapeutics Benzinga
Jan-24-19 10:46AM  Vertex Terminates COO Ian Smith on Code of Conduct Violation Zacks
Jan-23-19 08:18AM  Better Buy: CRISPR Therapeutics vs. Editas Medicine Motley Fool -5.08%
Jan-22-19 06:55PM  Should You Sell CRISPR Therapeutics Following an Analyst Downgrade? Motley Fool -10.91%
11:50AM  Here's Why CRISPR Therapeutics Stock Fell Today Motley Fool
07:00AM  CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies GlobeNewswire
Jan-19-19 05:55PM  Could CRISPR Therapeutics Be a Millionaire-Maker Stock? Motley Fool
Jan-18-19 12:55PM  4 Gene-Editing Technologies That Could Replace CRISPR Motley Fool
Jan-12-19 12:00PM  Where Will CRISPR Therapeutics Be in 10 Years? Motley Fool
Jan-11-19 04:14PM  Why This IBD Stock Of The Day Broke Out Despite Biotech Turbulence Investor's Business Daily
Jan-10-19 03:36PM  The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29% Motley Fool -5.88%
08:15AM  4 Reasons Editas Medicine's Future Looks Really Bright Motley Fool
Jan-09-19 11:21AM  CRISPR cadre: Check out the 12 Mass. companies exploring gene editing American City Business Journals +8.00%
09:15AM  Market's Newfound Optimism Brings Another 1% Gain Zacks
Jan-07-19 10:03AM  Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag Zacks +13.05%
08:23AM  Here's Why CRISPR Therapeutics Tanked 25.5% in December Motley Fool
Jan-06-19 09:09AM  Better Buy: CRISPR Therapeutics vs. Vertex Pharmaceuticals Motley Fool
Jan-04-19 05:11PM  What Happened in the Stock Market Today Motley Fool +8.03%
04:24PM  These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy Investor's Business Daily
07:00AM  CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease GlobeNewswire
Jan-03-19 10:33AM  Vertex teams up with Feng Zhang startup on gene editing tech American City Business Journals -6.19%
Dec-31-18 11:42AM  Dow Rises 91 Points Because Everybodys Ready for a New Year Barrons.com +6.80%
Dec-27-18 12:27PM  3 Gene Therapy Stocks to Play Biotechs Future InvestorPlace
09:15AM  Christmas Comes a Day Late Zacks
Dec-24-18 09:37AM  Don't Miss Chinese Biotechs Motley Fool +7.44%
Dec-21-18 11:25AM  Did Chinas Designer Babies Just Open Pandoras Box? Motley Fool -17.10%
Dec-19-18 10:55PM  Is CRISPR Therapeutics AG (CRSP) Going to Burn These Hedge Funds? Insider Monkey
09:12AM  Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint Zacks
05:37AM  Waltham's Eloxx aims to reach cystic fibrosis patients that Vertex can't American City Business Journals
Dec-18-18 09:35AM  Gene-Editing Stocks Took Stutter Steps Forward in 2018 Motley Fool -6.46%
09:10AM  Under Armour Tanks on Guidance Motley Fool
Dec-16-18 09:07AM  2 Sets of Disasters Biotech Will Pay For in 2019 Motley Fool
Dec-13-18 01:04PM  3 High-Growth Stocks That Are Just Getting Started Motley Fool -8.08%
10:13AM  Top 10 Healthcare Stories of 2018 Motley Fool
Dec-10-18 04:31PM  Why CRSP Stock Has Added Layers of Risk InvestorPlace
12:54PM  Here's Why Crispr Therapeutics Rose 17% in November Motley Fool
12:42PM  Here's Why Editas Medicine Jumped 23% in November Motley Fool
Dec-01-18 11:24AM  Genetic editing is this week's champ Fed's Powell is the chump Yahoo Finance
Nov-30-18 05:45PM  CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know Zacks
04:14PM  This Biotech Stock Could Launch Its First CRISPR Drug In 2022 Investor's Business Daily
10:31AM  Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018 Motley Fool
Nov-26-18 04:22PM  With genetically edited babies, a scientist transgresses a moral boundary MarketWatch
02:46PM  Mass. biotech leaders voice alarm over report of first gene-edited babies American City Business Journals
Nov-21-18 07:00AM  CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire +7.12%
Nov-18-18 04:51PM  Better Buy: CRISPR Therapeutics AG vs. Sangamo Therapeutics Inc. Motley Fool
Nov-13-18 08:45AM  New Research Coverage Highlights CAS Medical, Saia, Core Laboratories N.V, Perceptron, CRISPR Therapeutics AG, and IEC Electronics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-12-18 05:50PM  CRISPR Therapeutics AG (CRSP) Stock Moves -0.55%: What You Should Know Zacks
11:51AM  3 DNA Stocks That Are on the Uptrend InvestorPlace
Nov-09-18 07:00AM  CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology GlobeNewswire
Nov-07-18 07:46PM  Cambridge's Editas asks FDA to start gene editing trial American City Business Journals +10.81%
04:33PM  CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-05-18 02:13PM  Here's Why CRISPR Stocks Fell as Much as 40.7% in October Motley Fool
09:35AM  ImmunoGen (IMGN) Beats on Earnings in Q3, Lowers Guidance Zacks
07:55AM  5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings Zacks
Nov-02-18 11:31AM  VIVUS (VVUS) Q3 Loss Narrower Than Expected, Revenues Up Y/Y Zacks
09:15AM  Geron's (GERN) Q3 Earnings Beat, Revenues Miss, Shares Down Zacks
Nov-01-18 11:03AM  Ophthotech (OPHT) Q3 Earnings Beat, Gene Therapy in Focus Zacks +8.61%
Oct-31-18 11:23AM  Is a Beat in Store for Editas (EDIT) This Earnings Season? Zacks
Oct-30-18 09:48AM  Is a Beat in Store for CRISPR (CRSP) This Earnings Season? Zacks
Oct-29-18 01:44PM  Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2 Zacks
Oct-26-18 03:41PM  3 Stocks to Buy and Hold for the Next 50 Years Motley Fool
Oct-24-18 08:23PM  Vertex Pharmaceuticals Inc (VRTX) Q3 2018 Earnings Conference Call Transcript Motley Fool -9.17%
Oct-22-18 12:08PM  Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks
Oct-21-18 06:33AM  Better Buy: CRISPR Therapeutics AG vs. Intellia Therapeutics Inc. Motley Fool
Oct-14-18 02:34PM  Treating Genetic Diseases in Utero Could Change the CRISPR Space GuruFocus.com
Oct-12-18 02:23PM  3 High-Reward Stocks From 3 Emerging Trends InvestorPlace
12:48PM  FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial American City Business Journals
09:35AM  Company News For Oct 12, 2018 Zacks
Oct-11-18 05:16PM  Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts Zacks
01:50PM  Here's Why CRISPR Therapeutics Has Lost One-Third of Its Value Since September Motley Fool
08:49AM  Why CRISPR Therapeutics Stock Is Heading Higher Today Motley Fool
08:00AM  Today's Research Reports on Trending Tickers: CRISPR Therapeutics and Myriad Genetics ACCESSWIRE
06:25AM  CRISPR Therapeutics Set to Surge After FDA Lifts Hold on Human Trial Investopedia
Oct-10-18 05:11PM  After-hours buzz: SQ, FLR & more CNBC
05:03PM  FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial American City Business Journals
04:12PM  Crispr stock up 8% as company says FDA accepted new-drug application MarketWatch
04:01PM  CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease GlobeNewswire
Oct-09-18 04:35PM  Better Buy: Crispr Therapeutics AG vs. Editas Motley Fool
04:19PM  FDA Sets Action Date for Recro's Pain Management Candidate Zacks
10:21AM  Bausch's Bryhali Gets Tentative FDA Nod for Plaque Psoriasis Zacks
Oct-05-18 07:05PM  Cramer's lightning round: Watch outmomentum stocks are o... CNBC Videos
03:13PM  Who Are The Top Investors In CRISPR Therapeutics AG (NASDAQ:CRSP)? Simply Wall St.
Oct-02-18 10:30AM  Global Stem Cell Market Expected to Reach $270.5 Billion ACCESSWIRE -6.19%
07:00AM  CRISPR Therapeutics to Present at the Chardan Genetic Medicines Conference GlobeNewswire
Sep-27-18 01:55PM  Guide to CRISPR Stocks & Latest Apple, Fed, GDP News | Free Lunch Zacks
Sep-21-18 04:32PM  Here's Why CRISPR Therapeutics AG Fell as Much as 10.8% Today Motley Fool -9.19%
Sep-20-18 08:33PM  CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares GlobeNewswire -5.59%
09:02AM  The Daily Biotech Pulse: Adverum Snags Fast Track Designation, Crispr To Offer Shares, Elanco Animal Health To Debut Benzinga
08:32AM  Dow Jones Futures: Tilray, Marijuana Stocks Still Buzzing; Red Hat, Crispr Move On News Investor's Business Daily
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; ViaCyte, Inc. for designing allogeneic cell therapies derived from gene edited human stem cells for use in the treatment of diabetes type 1, diabetes type 2, and insulin dependent diabetes; and collaboration and license agreement with ProBioGen AG to develop novel in vivo delivery modalities for CRISPR/Cas9. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novak RodgerPresidentJan 09Sale35.0182,6902,894,9771,048,007Jan 10 04:09 PM
Novak RodgerPresidentJan 08Sale35.0917,310607,4081,130,697Jan 10 04:09 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 27Buy24.9527,461685,1165,380,940Dec 28 04:34 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 26Buy24.8912,737317,0775,353,479Dec 28 04:34 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 24Buy24.5868,0001,671,4825,340,742Dec 26 04:35 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 21Buy22.5822,742513,4785,272,742Dec 26 04:35 PM
EMSTER KURT VONDirectorDec 18Sale29.7069,9252,077,1011,164,268Dec 19 04:22 PM
EMSTER KURT VONDirectorDec 17Sale33.173,00999,7971,234,193Dec 19 04:22 PM
Kulkarni SamarthChief Executive OfficerDec 07Option Exercise1.8121,50038,915167,290Dec 11 04:29 PM
CELGENE CORP /DE/10% OwnerNov 21Sale19.2580,0001,540,0004,173,019Dec 07 09:57 AM
CAGNONI PABLO JDirectorJul 05Option Exercise5.591,6849,4141,684Jul 05 06:25 PM
CAGNONI PABLO JDirectorJul 05Sale62.001,684104,4080Jul 05 06:25 PM
CAGNONI PABLO JDirectorJul 03Option Exercise5.595,81632,5115,816Jul 05 06:25 PM
CAGNONI PABLO JDirectorJul 03Sale62.005,816360,5920Jul 05 06:25 PM
EMSTER KURT VONDirectorJun 05Sale12.5192011,50918,316Jun 07 04:36 PM
Kulkarni SamarthChief Executive OfficerJun 01Option Exercise1.8115,00027,150163,560Jun 05 08:20 PM
Kulkarni SamarthChief Executive OfficerJun 01Sale69.3615,0001,040,400148,560Jun 05 08:20 PM
Novak RodgerPresidentMay 17Option Exercise8.2775,000620,4241,223,007May 21 04:54 PM
Novak RodgerPresidentMay 17Sale60.0075,0004,500,0001,148,007May 21 04:54 PM
Bolzon Bradley J PhDDirectorMay 15Sale57.9944,0002,551,440640,014May 17 05:15 PM
Woiwode ThomasDirectorMay 15Sale57.9944,0002,551,440640,014May 17 05:11 PM
EMSTER KURT VONDirectorMay 14Sale55.36400,00022,142,5561,237,202May 15 08:04 PM
EMSTER KURT VONDirectorMay 11Sale52.84250,00013,209,9001,637,202May 15 08:04 PM
Bolzon Bradley J PhDDirectorMay 08Sale50.549,241467,06734,745May 09 05:14 PM
Woiwode ThomasDirectorMay 08Sale51.451,65385,0475,629May 09 05:15 PM
Bolzon Bradley J PhDDirectorMay 07Sale50.38119,7096,030,82634,977May 09 05:14 PM
Woiwode ThomasDirectorMay 07Sale50.38119,7096,030,82634,977May 09 05:15 PM
Bolzon Bradley J PhDDirectorApr 30Sale50.2930,5661,537,13838,064May 02 06:00 PM
Woiwode ThomasDirectorApr 30Sale50.2930,5661,537,13838,064May 02 06:00 PM
Bolzon Bradley J PhDDirectorApr 27Sale50.0211,648582,65538,852Apr 30 08:58 PM
Woiwode ThomasDirectorApr 27Sale50.0211,648582,65538,852Apr 30 08:57 PM
Bolzon Bradley J PhDDirectorApr 26Sale50.11210,61010,553,78239,152Apr 30 08:58 PM
Woiwode ThomasDirectorApr 26Sale50.11210,61010,553,78239,152Apr 30 08:57 PM
Woiwode ThomasDirectorApr 24Sale50.9922,8411,164,65544,582Apr 26 05:01 PM
Bolzon Bradley J PhDDirectorApr 24Sale50.9922,8411,164,65544,582Apr 26 04:57 PM
Versant Venture Capital V, L.P10% OwnerApr 24Sale50.9922,8411,164,65544,582Apr 26 04:44 PM
Versant Venture Capital IV, L.10% OwnerApr 23Sale50.68101,9945,168,90145,171Apr 24 07:44 PM
Woiwode ThomasDirectorApr 23Sale50.68101,9945,168,90145,171Apr 24 07:42 PM
Bolzon Bradley J PhDDirectorApr 23Sale50.68101,9945,168,90145,171Apr 24 07:41 PM